Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020
Subscribe To Our Newsletter & Stay Updated